Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Summit Therapeutics, Inc. shares rebounded in after-hours trading on Monday after a 14% selloff during regular hours, with ...

Q4 2024 Management View Co-CEO Bob Duggan emphasized recent milestones, including a clinical trial collaboration with Pfizer to evaluate ivonescimab in combination with Pfizer’s antibody-drug ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...

Robert Duggan; Executive Chairman of the Board, Co-Chief Executive Officer; Summit Therapeutics Inc Mahkam Zanganeh; President, Co-Chief Executive Officer, Director; Summit Therapeutics Inc Manmeet ...

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.

智通财经APP获悉，Summit Therapeutics公司今天宣布，与辉瑞 (PFE.US)开展临床试验合作， 评估在研靶向PD-1/VEGF的双特异性抗体ivonescimab，与辉瑞的多种抗体偶联药物 (ADCs)联用，治疗多种实体瘤的效果。

Summit Therapeutics公司今天宣布，与辉瑞（Pfizer）开展临床试验合作，评估在研靶向PD-1/VEGF的双特异性抗体ivonescimab，与辉瑞的多种抗体偶联药物（ADCs）联用，治疗多种实体瘤的效果。

Chinese scientists are celebrating a new breakthrough cancer drug, but some Chinese citizens are skeptical of domestically ...